US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case

  • Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients
  • Sandoz is disappointed US patients affected by chronic autoimmune and inflammatory disease have to wait until 2029 for availability of biosimilar Erelzi
  • Sandoz remains committed to pioneering access for patients and contributing to more …
/by